En undersøgelse, der observerer langsigtet, effektivitet og sikkerhed for Odevixibat (Bylvay) hos patienter med Alagille Syndrome (ALGS), der modtager løbende behandling
Prospektiv registerbaseret undersøgelse, der evaluerer effektiviteten og sikkerheden af Odevixibat hos deltagere med Alagille Syndrome (ALGS)
This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives.
Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching.
The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Studieoversigt
Status
Status
Betingelser
Betingelser
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Ipsen Recruitment Enquiries
- Telefonnummer: See email
- E-mail: clinical.trials@ipsen.com
Studiesteder
-
-
California
-
Los Angeles, California, Forenede Stater, 90027
- Rekruttering
- Children's Hospital Los Angeles
-
San Francisco, California, Forenede Stater, 94158
- Rekruttering
- UCSF Benioff Children's Hospital
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64108
- Rekruttering
- The Children's Mercy Hospital
-
St Louis, Missouri, Forenede Stater, 63104
- Rekruttering
- SSM Health Cardinal Glennon Children's Hospital
-
-
New York
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- NYU Langone - NYU Grossman School of Medicine
-
New York, New York, Forenede Stater, 10032
- Rekruttering
- Columbia University Medical Center - Morgan Stanley Children's Hospital of NewYork - Presbyterian (MS-CHONY)
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38105
- Rekruttering
- Le Bonheur Children's Hospital
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75246
- Rekruttering
- Children's Medical Center Of Dallas
-
El Paso, Texas, Forenede Stater, 79902
- Rekruttering
- Proactive El Paso,LLC
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84113
- Ikke rekrutterer endnu
- Primary Children's Hospital (PCH) - Intermountain Healthcare/University of Utah
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients diagnosed with ALGS who start treatment with odevixibat (Bylvay) will be enrolled into the registry. Patients who started odevixibat treatment before the implementation of the registry study may also be enrolled.
Beskrivelse
Inclusion Criteria:
- Diagnosed with ALGS.
- On (or starting) active odevixibat treatment.
- Signed informed consent and assent, as appropriate. Consent/assent from the participant or legal representative should be obtained, as appropriate, before any study data collection is conducted. Participants who turn 18 years of age (or legal age per country) while participating in the study will be required to provide consent for themselves.
Exclusion Criteria:
- Currently participating in a clinical trial with odevixibat.
- Currently participating in any interventional clinical trial for ALGS.
- Have any contraindication to odevixibat as per the locally approved label.
- Had liver transplant before enrolment
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: OTHER
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Procentdel af deltagere med Alagille Syndrome (ALGS), der behandles med Odevixibat og gennemgår galdedigningsoperation eller levertransplantation.
Tidsramme: Fra første dosis til slutningen af studiet (ca. 5 års dataindsamling)
|
Fra første dosis til slutningen af studiet (ca. 5 års dataindsamling)
|
|
|
Surgical biliary diversion-free survival
Tidsramme: From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to the first occurrence of surgical biliary diversion or death. |
From first dose to end of study (approximately 5 years data collection)
|
|
Liver transplant-free survival
Tidsramme: From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to the first occurrence of liver transplant or death. |
From first dose to end of study (approximately 5 years data collection)
|
|
Overall survival
Tidsramme: From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to death. |
From first dose to end of study (approximately 5 years data collection)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in Weight
Tidsramme: From first dose to end of study (approximately 5 years data collection)
|
This endpoint will measure the change in participants' weight from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations. |
From first dose to end of study (approximately 5 years data collection)
|
|
Change from Baseline in Height
Tidsramme: From first dose to end of study (approximately 5 years data collection)
|
This endpoint will measure the change in participants' height from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations. |
From first dose to end of study (approximately 5 years data collection)
|
|
Percentage of participants with Adverse Events (AEs) associated with fat-soluble vitamin (FSV) deficiencies and their possible sequelae.
Tidsramme: From signing of the Informed Consent Form (ICF) to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the Informed Consent Form (ICF) to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with suspected hepatotoxic Adverse events (AEs) requiring interruption of odevixibat
Tidsramme: From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with bleeding AEs
Tidsramme: From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with AEs
Tidsramme: From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Ipsen Medical, Director, Ipsen
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjerte-kar-sygdomme
- Genetiske sygdomme, medfødte
- Sygdomme i fordøjelsessystemet
- Galdevejssygdomme
- Leversygdomme
- Medfødte abnormiteter
- Kardiovaskulære abnormiteter
- Hjertefejl, medfødt
- Abnormiteter, multiple
- Galdevejssygdomme
- Kolestase, intrahepatisk
- Kolestase
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Alagille syndrom
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CLIN-60240-033
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD-delingstidsramme
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
IPD-delingsadgangskriterier
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .